14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
IMMX vs MTNB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). IMMX carries a Unified Composite Score of 56.7/100 (HOLD) at $7.04 (N/M Forward P/E, 0.0% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs MTNB. Trailing 12-month operating profitability (IMMX 0.0% vs MTNB 0.0%) and valuation multiples (IMMX N/M vs MTNB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IMMX vs MTNB Key Questions & Quantitative Answers
As of Nov 19, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). IMMX carries a Unified Composite Score of 56.7/100 (HOLD) at $7.04 (N/M Forward P/E, 0.0% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMMX leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus N/A for MTNB. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.
IMMX and MTNB trade at balanced relative valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus MTNB (-147.5% ROE) capital efficiency.
In options market volatility and institutional positioning, IMMX carries 100.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 76% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.